ClinicalTrials.gov
public full text
Public Domain
Sapropterin as a Treatment for Autistic Disorder
This study is intended to provide a definitive test of the hypothesis that elevating sapropterin (tetrahydrobiopterin, a cofactor for several key brain enzymes)concentrations in the CNS will result in measurable improvements in core symptoms of autism in young individuals, under age 6 years. The study will entail a double-blind, placebo-controlled 16-week intervention.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Autism prevalence and the limits of diagnostic expansion: a perspective on diagnostic validity, adult assessment, and phenotypic stratification.#433744
- Correção de erros no ensino de crianças diagnosticadas com o Transtorno do Espectro Autista (TEA)#446932
- Genetics, Brain Structure and Thinking Skills in Autism#1124937
- Validation of Indiana's Early Evaluation Hub System#1375981
- A Multi-site Comparison of Social Visual Engagement to Clinical Diagnosis for Autism Spectrum Disorder#968532
Record · ID 1454048
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive